Literature DB >> 11959609

Different aminoglycoside-resistant phenotypes in a rabbit Staphylococcus aureus endocarditis infection model.

N Asseray1, J Caillon, N Roux, C Jacqueline, R Bismuth, M F Kergueris, G Potel, D Bugnon.   

Abstract

The impact of different types of enzymatic resistance on the in vivo antibacterial activity of aminoglycosides (amikacin, gentamicin, and netilmicin) was studied in the rabbit endocarditis model with four strains of Staphylococcus aureus. Animals were treated in a manner simulating the administration of a single daily human dose. Amikacin had no effect on the three kanamycin-resistant strains despite apparent susceptibility in the disk diffusion test. Gentamicin appears to be the preferable aminoglycoside for treatment of staphylococcal infections.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 11959609      PMCID： PMC127149          DOI： 10.1128/AAC.46.5.1591-1593.2002

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  16 in total

Review 1.  Pharmacokinetic and pharmacodynamic requirements for antibiotic therapy of experimental endocarditis.

Authors:  A C Cremieux; C Carbon
Journal:  Antimicrob Agents Chemother       Date:  1992-10       Impact factor: 5.191

2.  Once-daily aminoglycoside in the treatment of Enterococcus faecalis endocarditis: case report and review.

Authors:  V H Tam; P S Mckinnon; D P Levine; S M Brandel; M J Rybak
Journal:  Pharmacotherapy       Date:  2000-09       Impact factor: 4.705

3.  Effect of aminoglycoside concentration on reaction rates of aminoglycoside-modifying enzymes.

Authors:  G P Bongaerts; J S Vliegenthart
Journal:  Antimicrob Agents Chemother       Date:  1988-05       Impact factor: 5.191

4.  Emergence and spread in French hospitals of methicillin-resistant Staphylococcus aureus with increasing susceptibility to gentamicin and other antibiotics.

Authors:  H Lelièvre; G Lina; M E Jones; C Olive; F Forey; M Roussel-Delvallez; M H Nicolas-Chanoine; C M Bébéar; V Jarlier; A Andremont; F Vandenesch; J Etienne
Journal:  J Clin Microbiol       Date:  1999-11       Impact factor: 5.948

5.  Antibiotic treatment of adults with infective endocarditis due to streptococci, enterococci, staphylococci, and HACEK microorganisms. American Heart Association.

Authors:  W R Wilson; A W Karchmer; A S Dajani; K A Taubert; A Bayer; D Kaye; A L Bisno; P Ferrieri; S T Shulman; D T Durack
Journal:  JAMA       Date:  1995-12-06       Impact factor: 56.272

6.  Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration.

Authors:  R D Moore; P S Lietman; C R Smith
Journal:  J Infect Dis       Date:  1987-01       Impact factor: 5.226

Review 7.  Methicillin-resistant Staphylococcus aureus: a consensus review of the microbiology, pathogenesis, and epidemiology with implications for prevention and management.

Authors:  M E Mulligan; K A Murray-Leisure; B S Ribner; H C Standiford; J F John; J A Korvick; C A Kauffman; V L Yu
Journal:  Am J Med       Date:  1993-03       Impact factor: 4.965

8.  Purification and characterization of aminoglycoside-modifying enzymes from Staphylococcus aureus and Staphylococcus epidermidis.

Authors:  K Ubukata; N Yamashita; A Gotoh; M Konno
Journal:  Antimicrob Agents Chemother       Date:  1984-06       Impact factor: 5.191

9.  Prevalence and mechanisms of aminoglycoside resistance. A ten-year study.

Authors:  I Phillips; A King; K Shannon
Journal:  Am J Med       Date:  1986-06-30       Impact factor: 4.965

10.  Gene homogeneity for aminoglycoside-modifying enzymes in gram-positive cocci.

Authors:  H Ounissi; E Derlot; C Carlier; P Courvalin
Journal:  Antimicrob Agents Chemother       Date:  1990-11       Impact factor: 5.191
View more
  3 in total

1.  The optimal aminoglycoside and its dosage for the treatment of severe Enterococcus faecalis infection. An experimental study in the rabbit endocarditis model.

Authors:  L Dubé; J Caillon; C Jacqueline; D Bugnon; G Potel; N Asseray
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-03-08       Impact factor: 3.267

2.  Aminoglycoside-resistance mechanisms in multidrug-resistant Staphylococcus aureus clinical isolates.

Authors:  R Kelmani Chandrakanth; S Raju; S A Patil
Journal:  Curr Microbiol       Date:  2008-03-05       Impact factor: 2.188

3.  Combination of quinupristin-dalfopristin and gentamicin against methicillin-resistant Staphylococcus aureus: experimental rabbit endocarditis study.

Authors:  Eric Batard; Cedric Jacqueline; David Boutoille; Antoine Hamel; Henri B Drugeon; Nathalie Asseray; Roland Leclercq; Jocelyne Caillon; Gilles Potel; Denis Bugnon
Journal:  Antimicrob Agents Chemother       Date:  2002-07       Impact factor: 5.191
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.